Taysha Gene Therapies (TSHA) vs Vor Biopharma (VOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Taysha Gene Therapies (TSHA) has outperformed Vor Biopharma (VOR) over the past year, losing 12.5% versus a loss of 42.7%. Over five years, TSHA leads with a -75.2% price change compared with -93.8% for VOR. Taysha Gene Therapies is the larger company by market cap ($1.44 billion vs $1.13 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TSHA | VOR |
|---|---|---|
| Share price | $4.43 | $19.13 |
| Market cap | $1.44B | $1.13B |
| 1-day change | 0.00% | +1.86% |
| YTD return | -19.45% | +46.25% |
| 1-year return | -12.45% | -42.72% |
| 5-year return | -75.22% | -93.81% |
| P/E ratio (TTM) | — | 0.11 |
| EPS (TTM) | $-0.41 | $180.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.30 | $33.50 |
| 52-week low | $3.69 | $6.50 |
| Distance from 52-week high | -39.32% | -42.90% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +193.45% | +103.87% |
| Average volume | 3.28M | 989.57K |
| Shares outstanding | 325.83M | 59.16M |
| Employees | 99 | 76 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TSHA has outperformed VOR by 30.3 percentage points over the past year.
- The two companies sit in different sectors: Taysha Gene Therapies in Healthcare and Vor Biopharma in Health Care.
About Taysha Gene Therapies
TSHA stock →Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
Healthcare · Biotechnology · 99 employees
About Vor Biopharma
VOR stock →Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 76 employees
TSHA vs VOR FAQ
Which is bigger, Taysha Gene Therapies or Vor Biopharma?
Taysha Gene Therapies (TSHA) is larger, with a market capitalization of $1.44B compared with $1.13B for Vor Biopharma (VOR).
Which stock has performed better over the past year, TSHA or VOR?
TSHA returned -12.45% over the past 12 months, compared with -42.72% for VOR (price return, excluding dividends). Past performance does not predict future results.
Are Taysha Gene Therapies and Vor Biopharma in the same industry?
No. Taysha Gene Therapies is in the Healthcare sector, while Vor Biopharma is in Health Care.